The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characterizing clinical trials for CAR T targeting solid tumors from 2018 to 2023: A systematic review.
 
William Wesson
No Relationships to Disclose
 
Fathima Shehnaz Ayoobkhan
No Relationships to Disclose
 
Zahra Mahmoudjafari
Honoraria - Bristol Myers Squibb Foundation; Genentech; Incyte; Kite/Gilead; Merck; Omeros; SeaGen
Consulting or Advisory Role - Genentech
Speakers' Bureau - Omeros
 
Muhammad Umair Mushtaq
No Relationships to Disclose
 
Al-Ola A. Abdallah
Research Funding - Abbvie (Inst); Bristol-Myers Squibb/Medarex (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Sanofi (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - PSA vaccine patent
 
Weijing Sun
Honoraria - Astellas Pharma; Merck
Consulting or Advisory Role - AstraZeneca; Macrogenics
Research Funding - AstraZeneca (Inst); Merck (Inst); Novella Clinical (Inst)
 
Faiz Anwer
Consulting or Advisory Role - BMS; Janssen
Speakers' Bureau - Bristol Myers Squibb Foundation
Research Funding - Abbvie (Inst); Acetylon Pharmaceuticals (Inst); Astellas Pharma (Inst); Bristol Myers Squibb (Inst); Caribou Biosciences; Caribou Biosciences (Inst); Celgene (Inst); Janssen (Inst); Millennium (Inst)
Travel, Accommodations, Expenses - Bristol Myers Squibb
 
Gary C. Doolittle
Speakers' Bureau - Bristol-Myeres Squibb; Merck Sharp & Dohme; Novartis
 
Joseph McGuirk
Honoraria - AlloVir; Kite, a Gilead company; Magenta Therapeutics; Nektar; Sana Biotechnology
Consulting or Advisory Role - Allovir; crispr therapeutics; EcoR1 Capital; Juno Therapeutics; Kite, a Gilead company; Magenta Therapeutics
Speakers' Bureau - Kite/Gilead
Research Funding - AlloVir (Inst); Astellas Pharma (Inst); Bellicum Pharmaceuticals (Inst); Fresenius Biotech (Inst); Gamida Cell (Inst); Kite, a Gilead company (Inst); Novartis (Inst); Novartis (Inst); Pluristem Therapeutics (Inst)
Travel, Accommodations, Expenses - Kite, a Gilead company; SITC/ACCC; Syncopation Life Sciences
 
Raed Moh'd Taiseer Al-Rajabi
Stock and Other Ownership Interests - Actinium Pharmaceuticals; Seagen
Consulting or Advisory Role - AstraZeneca; Bayer
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Lexicon (Inst); Lilly (Inst); Merck (Inst); Sillajen (Inst)
 
Joaquina Celebre Baranda
Stock and Other Ownership Interests - Aprea Therapeutics; Merus NV; Moderna Therapeutics; Zymeworks
Research Funding - Astellas Pharma (Inst); Chungchun Intellicrown (Inst); Exelixis (Inst); IMPAC Medical Systems (Inst); Merck (Inst); Poseida (Inst); Sanofi (Inst); Synermore (Inst); Xencor (Inst)
 
Nausheen Ahmed
Consulting or Advisory Role - BMS; Kite/ Gilead
Research Funding - Kite/Gilead (Inst)